secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2023-03-24T23:59:59+00:00
Accession:  0001193125-23-079104
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Pharmaceuticals amends bylaws to update proxy rules and conform to Delaware law
--------------------------------------------------------------------------------

- Enhanced disclosure requirements for stockholder nominations and proposals.
- Adopted procedural changes to align with SEC universal proxy rules.
- Revised meeting provisions per recent DGCL amendments (notice, quorum, adjournment).
- Updated exclusive forum provisions and officer/committee authority.
- Made ministerial clarifications and conforming revisions throughout.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312523079104/0001193125-23-079104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312523079104/d487262d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-079104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer